Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Exemption of Laboratories Licensed by the State of Washington, 22406-22408 [2024-06802]
Download as PDF
22406
Federal Register / Vol. 89, No. 63 / Monday, April 1, 2024 / Notices
and wealth building, with a particular
focus on the concerns of low- and
moderate-income consumers and
communities. Candidates do not have to
be experts on all topics related to
consumer financial services or
community development, but they
should possess some basic knowledge of
these areas and related issues. In
appointing members to the CAC, the
Board will consider a number of factors,
including diversity in terms of subject
matter expertise, geographic
representation, and the representation of
women and minority groups.
CAC members must be willing and
able to make the necessary time
commitment to participate in
organizational conference calls and
prepare for and attend meetings two
times per year (usually for two days).
The meetings will be held at the Board’s
offices in Washington, DC. The Board
will provide a nominal honorarium and
will reimburse CAC members only for
their actual travel expenses subject to
Board policy.
By order of the Board of Governors of
the Federal Reserve System, acting
through the Director of the Division of
Consumer and Community Affairs
under delegated authority, March 25,
2024.
of receipt will be provided within a
week of submission.
DATES: Letters of nomination and
resumes should be submitted no later
than May 3, 2024, to ensure adequate
opportunity for review and
consideration of nominees prior to
appointment.
Ann E. Misback,
Secretary of the Board.
[CMS–3441–N]
[FR Doc. 2024–06766 Filed 3–29–24; 8:45 am]
Medicare, Medicaid, and CLIA
Programs; Clinical Laboratory
Improvement Amendments of 1988
Exemption of Laboratories Licensed
by the State of Washington
BILLING CODE 6210–01–P
GOVERNMENT ACCOUNTABILITY
OFFICE
Government Accountability
Office (GAO).
ACTION: Request for letters of
nomination and resumes.
AGENCY:
The Patient Protection and
Affordable Care Act gave the
Comptroller General of the United
States responsibility for appointing up
to 21 members to the Board of
Governors of the Patient-Centered
Outcomes Research Institute. In
addition, the Directors of the Agency for
Healthcare Research and Quality and
the National Institutes of Health, or their
designees, are members of the Board. As
the result of terms ending in September
2024, GAO is accepting nominations in
the following category: a representative
of a Federal health program or agency.
Nominations should be sent to the email
address listed below. Acknowledgement
ddrumheller on DSK120RN23PROD with NOTICES1
VerDate Sep<11>2014
17:17 Mar 29, 2024
Jkt 262001
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2024–06777 Filed 3–29–24; 8:45 am]
BILLING CODE 1610–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
Request for Nominations for the Board
of Governors of the Patient-Centered
Outcomes Research Institute (PCORI)
SUMMARY:
Submit letters of
nomination and resumes to PCORI@
gao.gov. Include PCORI nominations in
the subject line of the email.
FOR FURTHER INFORMATION CONTACT: Ray
Sendejas at (202) 512–7113 or
SendejasR@gao.gov if you do not
receive an acknowledgement or need
additional information. For general
information, contact GAO’s Office of
Public Affairs, (202) 512–4800.
Authority: 42 U.S.C. 1320e; 26 U.S.C.
9511.
ADDRESSES:
This notice announces that
laboratories located in and licensed by
the State of Washington that possess a
valid license under the Medical Test
Site law, chapter 70.42 of the Revised
Code of Washington, are exempt from
the requirements of the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) for a period of 4 years.
DATES: The exemption granted by this
notice is effective from April 1, 2024 to
April 1, 2028.
FOR FURTHER INFORMATION CONTACT:
Mary Hasan, (410) 786–6480.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background and Legislative
Authority
Section 353 of the Public Health
Service Act (PHSA), as amended by the
Clinical Laboratory Improvement
Amendments of 1988 (CLIA) (Pub. L.
100–578), which was enacted on
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
October 31, 1988, generally provides
that no laboratory may perform tests on
human specimens for the diagnosis,
prevention or treatment of any disease
or impairment of, or assessment of the
health of, human beings unless it has a
certificate to perform that category of
tests issued by the Secretary of the
Department of Health and Human
Services (HHS). Under section
1861(s)(17)(A) of the Social Security Act
(the Act), the Medicare program will
only pay for laboratory services if the
laboratory has an appropriate CLIA
certificate for the testing they conduct.
Under section 1902(a)(9)(C) of the Act,
State Medicaid plans will generally only
pay for laboratory services furnished by
CLIA-certified laboratories. Thus,
although subject to specified
exemptions and exceptions, laboratories
generally must have a current and valid
CLIA certificate to test human
specimens for the purposes noted above
to be eligible for payment for those tests
by the Medicare or Medicaid programs.
Regulations implementing section 353
of the PHSA are contained in 42 CFR
part 493.
Section 353(p)(2) of the PHSA
provides for the exemption of
laboratories from CLIA requirements in
States that enact legal requirements that
are equal to or more stringent than
CLIA’s statutory and regulatory
requirements. Section 353(p)(2) of the
PHSA is implemented in subpart E of
our regulations at 42 CFR part 493.
Sections 493.551(a) and 493.553 provide
that CMS may exempt from CLIA
requirements, for a period not to exceed
6 years, all State-licensed or Stateapproved laboratories in a State if the
State licensure program meets the
specified conditions. Section 493.559(a)
provides that CMS will publish a notice
in the Federal Register when CMS
grants an exemption to an approved
State licensure program. Section
493.559(b) provides that the notice will
include the following:
• The name of the State licensure
program.
• A description of how the laboratory
requirements of the State are equal to or
more stringent than those of part 493.
• The basis for granting the
exemption.
• The term of approval, not to exceed
6 years.
A. State of Washington’s Application for
CLIA Exemption of Its Laboratories
The State of Washington has applied
for exemption of its laboratories from
CLIA program requirements. The State
of Washington submitted all the
applicable information and attestations
required by §§ 493.551(a), 493.553, and
E:\FR\FM\01APN1.SGM
01APN1
Federal Register / Vol. 89, No. 63 / Monday, April 1, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
493.557(b) for State licensure programs
seeking exemption of their licensed
laboratories from CLIA program
requirements. Examples of documents
and information submitted include: a
comparison of its laboratory licensure
requirements with the comparable CLIA
condition-level requirements (that is, a
crosswalk); and a description of the
following: its inspection process; its
proficiency testing (PT) monitoring
process; its data management and
analysis system; its investigative and
response procedures for complaints
received against laboratories; and its
policy regarding announced and
unannounced inspections.
B. CMS Analysis of Washington’s
Application and Supporting
Documentation
To determine whether CMS should
grant a CLIA exemption to laboratories
licensed by a State, CMS reviews the
application and additional
documentation that the State submits to
us and conducts a detailed and in-depth
comparison of the State licensure
program and CLIA’s statutory and
regulatory requirements to determine
whether the State licensure program
meets the requirements in part 493.
In summary, the State generally must
demonstrate that:
• It has State laws in effect that
provide for a State licensure program
that has requirements that are equal to,
or more stringent than, CLIA conditionlevel requirements for laboratories.
• It has implemented a State
licensure program with requirements
that are equal to, or more stringent than,
the CLIA condition-level requirements
such that a laboratory licensed by the
State program would meet the CLIA
condition-level requirements if it were
inspected against those requirements.
• The requirements under that State
licensure program meet or exceed the
requirements of §§ 493.553, 493.555,
and 493.557(b) and is suitable for
approval by CMS under § 493.553(b)(3).
For example, among other things, the
program would need to:
++ Demonstrate that it has
enforcement authority and
administrative structures and resources
adequate to enforce its laboratory
requirements.
++ Permit CMS or CMS agents to
inspect laboratories within the State.
++ Require laboratories within the
State to submit to inspections by CMS
or CMS agents as a condition of
licensure.
++ Agree to pay any costs associated
with our activities to validate its State
licensure program as specified in
§ 493.557(b)(4) as well as the State’s pro
VerDate Sep<11>2014
17:17 Mar 29, 2024
Jkt 262001
rata share of the general overhead to
develop and implement CLIA as
specified in § 493.649(a).
++ Take appropriate enforcement
action against laboratories found by
CMS or CMS agents to be out of
compliance with requirements
equivalent to CLIA requirements, as
specified in § 493.557(b).
As specified in our regulations at
§§ 493.555 and 493.557(b), our review of
a State licensure program includes (but
is not necessarily limited to) an
evaluation of the following:
• Whether the State’s requirements
for laboratories are equal to, or more
stringent than, the CLIA condition-level
requirements.
• The State’s inspection process
requirements to determine the
following:
++ The comparability of the full
inspection and complaint inspection
procedures to those of CMS, including,
but not limited to, inspection frequency
and the ability to investigate and
respond to complaints against its
laboratories.
++ The State’s enforcement
procedures for laboratories found to be
out of compliance with its requirements.
• The ability of the State to provide
CMS with electronic data and reports
with the adverse or corrective actions
resulting from PT results that constitute
unsuccessful participation in CMSapproved PT programs and with other
data CMS determines to be necessary for
validation review and assessment of the
State’s inspection process requirements.
• The State’s agreement with CMS
that requires the State to do the
following:
++ Notify CMS within 30 days of the
action taken against any CLIA-exempt
laboratory that has had its licensure or
approval suspended, withdrawn,
revoked, or limited; been in any way
sanctioned; or had any adverse action
taken against it.
++ Notify CMS within 10 days of any
deficiency identified in a CLIA-exempt
laboratory in cases when the deficiency
poses an immediate jeopardy to the
laboratory’s patients or a hazard to the
general public.
++ Notify each laboratory licensed by
the State under its approved State
licensure program within 10 days of a
withdrawal of our approval of the
State’s licensure program, and the
resulting loss of the laboratory’s
exemption from CLIA based on its
licensure under that program.
++ Provide CMS with written
notification of any changes in the State’s
licensure (or approval) and inspection
requirements.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
22407
++ Disclose to CMS or CMS’ agent
any laboratory’s PT results in
accordance with the State’s
confidentiality requirements.
++ Take appropriate enforcement
action against laboratories that CMS or
CMS agents find to be out of compliance
with CLIA condition-level requirements
and report these enforcement actions to
CMS.
++ Notify CMS within 30 days of all
newly licensed laboratories, including
the specialty and subspecialty areas of
testing, and notify CMS of any changes
in the specialties and subspecialties for
which any licensed laboratory in the
State performs testing.
++ Provide CMS with inspection
schedules, as requested, for validation
purposes.
In keeping with the process described
above, CMS evaluated the application
and supporting materials that were
submitted by Washington State to verify
that the laboratories licensed through its
program will meet or exceed the
requirements of the following subparts
of part 493:
• Subpart H, Participation in
Proficiency Testing for Laboratories
Performing Nonwaived Testing;
• Subpart J, Facility Administration
for Nonwaived Testing;
• Subpart K, Quality Systems for
Nonwaived Testing,
• Subpart M, Personnel for
Nonwaived Testing;
• Subpart Q, Inspection; and
• Subpart R, Enforcement Procedures.
CMS found that Washington State’s
laboratory licensure program
requirements mapped to all the CLIA
condition-level requirements. The State
licensure program’s inspection process
and PT monitoring processes were
adequate. Other materials that were
submitted demonstrated compliance
with the other above-referenced
requirements of subpart E of part 493.
As a result, CMS concluded that the
submitted documents supported
exempting laboratories licensed under
that program from the CLIA program
requirements. Furthermore, a review of
our validation inspections conducted by
the CMS office in Seattle, Washington,
supported this conclusion.
The Federal validation inspections of
CLIA-exempt laboratories, as specified
in § 493.563, were conducted on a
representative sample basis, as well as
in response to any substantial
allegations of noncompliance
(complaint inspections). The outcome of
those validation inspections has been
and will continue to be our principal
tool for verifying that the laboratories
located in, and licensed by, the State are
in compliance with CLIA requirements.
E:\FR\FM\01APN1.SGM
01APN1
22408
Federal Register / Vol. 89, No. 63 / Monday, April 1, 2024 / Notices
The CMS office in Seattle,
Washington, has conducted validation
inspections of a representative sample
of the laboratories inspected by the
Washington State Office of Laboratory
Quality Assurance (LQA). The
validation inspections were primarily of
the concurrent type; that is, our
surveyors accompanied Washington
State’s inspectors, each inspecting
against his or her agency’s respective
regulations. Analysis of the validation
data revealed no significant differences
between the State and Federal findings.
The validation surveys verified that the
State of Washington inspection process
covers all CLIA conditions applicable to
each laboratory being inspected and also
verified that the State laboratory
licensure requirements meet or exceed
CLIA condition-level requirements. The
validation surveys found the State
inspectors highly skilled and qualified.
The LQA inspected laboratories in a
timely fashion; that is, all laboratories
were inspected within the required 24month cycle. All parameters monitored
by the CMS office in Seattle,
Washington, to date, indicate that the
State of Washington is meeting all
requirements for approval of CLIA
exemption. This Federal monitoring
will continue as an on-going process.
ddrumheller on DSK120RN23PROD with NOTICES1
C. Conclusion
Based on review of the documents
submitted by the Washington State
licensure program under the
requirements of subpart E of part 493, as
well as the outcome of the validation
inspections conducted by the CMS
office in Seattle, Washington, CMS finds
that the State of Washington’s licensure
program meets the requirements of
§ 493.553(a), and that, as a result, CMS
may exempt all State-licensed
laboratories from CLIA program
requirements.
Approval of the CLIA exemption for
laboratories located within and licensed
by the State of Washington laboratory
licensure program is subject to removal
if CMS determines that the outcome of
a comparability review or a validation
review inspection is not acceptable, as
described under §§ 493.573 and
493.575, or if the State of Washington
fails to pay the required fee every 2
years as required under § 493.649.
D. Laboratory Data
The approval of this exemption for
laboratories located within and licensed
by the State of Washington is
conditioned on the State of
Washington’s continued compliance
with the assertions made in its
application, including the provision of
information to us in accordance with
VerDate Sep<11>2014
17:17 Mar 29, 2024
Jkt 262001
our regulations at § 493.557(b)(8) about
changes to a laboratory’s specialties or
subspecialties based on the State’s
survey, and changes to a laboratory’s
certification status.
E. Required Administrative Actions
CLIA is a user-fee funded program.
The registration fee paid by laboratories
is intended to cover the cost of the
development and administration of the
program. However, when a State’s
application for exemption is approved,
CMS does not charge a fee to
laboratories in the State. The State’s
share of the costs associated with CLIA
must be collected from the State, as
specified in § 493.649.
The State of Washington must pay for
the following:
• Costs of Federal inspections of
laboratories in the State to verify that
standards are being enforced in an
appropriate manner.
• Costs incurred for investigations of
complaints against State of Washington
laboratories if the complaint is
substantiated.
• The State’s pro rata share of general
overhead to administer the laboratory
certification program under section 353
of the PHS Act.
To estimate the State of Washington’s
proportionate share of the general
overhead costs to develop and
implement CLIA, CMS determined the
ratio of laboratories in the State to the
total number of laboratories nationally.
Approximately 1.9 percent of the
registered laboratories are in the State of
Washington. CMS determined that a
corresponding percentage of the
applicable CMS, CDC, FDA, and their
respective contractor costs should be
borne by the State of Washington.
The State of Washington has agreed to
pay the State’s pro rata share of the
anticipated overhead costs and costs of
actual validation (including complaint
investigation surveys) as specified in
§ 493.655(b). A final reconciliation for
all laboratories and all expenses will be
made. CMS will reimburse the State for
any overpayment or bill it for any
balance.
II. Approval
In light of the foregoing, CMS grants
approval of the State of Washington’s
laboratory licensure program under
subpart E. All laboratories located in
and licensed by the State of Washington
under the Medical Test Site law, chapter
70.42 of the Revised Code of
Washington, are CLIA-exempt for all
specialties and subspecialties until
April 1, 2028.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Trenesha Fultz-Mimms, who
is the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2024–06802 Filed 3–29–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Immigration Legal Services for Afghan
Arrivals—Eligible Afghan Arrivals
Intake Form and Intake Interview (New
Collection)
Office of Refugee Resettlement,
Administration for Children and
Families, U.S. Department of Health and
Human Services.
ACTION: Request for public comments.
AGENCY:
The Office of Refugee
Resettlement (ORR), Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS), is proposing to collect
data from Eligible Afghan Arrivals
(EAAs) in need of direct legal services
through Immigration Legal Services for
Afghan Arrivals (ILSAA) to determine
eligibility.
SUMMARY:
Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
DATES:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. You can also obtain
copies of the proposed collection of
information by emailing infocollection@
acf.hhs.gov. Identify all emailed
requests by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
E:\FR\FM\01APN1.SGM
01APN1
Agencies
[Federal Register Volume 89, Number 63 (Monday, April 1, 2024)]
[Notices]
[Pages 22406-22408]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06802]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3441-N]
Medicare, Medicaid, and CLIA Programs; Clinical Laboratory
Improvement Amendments of 1988 Exemption of Laboratories Licensed by
the State of Washington
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces that laboratories located in and
licensed by the State of Washington that possess a valid license under
the Medical Test Site law, chapter 70.42 of the Revised Code of
Washington, are exempt from the requirements of the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) for a period of 4 years.
DATES: The exemption granted by this notice is effective from April 1,
2024 to April 1, 2028.
FOR FURTHER INFORMATION CONTACT: Mary Hasan, (410) 786-6480.
SUPPLEMENTARY INFORMATION:
I. Background and Legislative Authority
Section 353 of the Public Health Service Act (PHSA), as amended by
the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (Pub. L.
100-578), which was enacted on October 31, 1988, generally provides
that no laboratory may perform tests on human specimens for the
diagnosis, prevention or treatment of any disease or impairment of, or
assessment of the health of, human beings unless it has a certificate
to perform that category of tests issued by the Secretary of the
Department of Health and Human Services (HHS). Under section
1861(s)(17)(A) of the Social Security Act (the Act), the Medicare
program will only pay for laboratory services if the laboratory has an
appropriate CLIA certificate for the testing they conduct. Under
section 1902(a)(9)(C) of the Act, State Medicaid plans will generally
only pay for laboratory services furnished by CLIA-certified
laboratories. Thus, although subject to specified exemptions and
exceptions, laboratories generally must have a current and valid CLIA
certificate to test human specimens for the purposes noted above to be
eligible for payment for those tests by the Medicare or Medicaid
programs. Regulations implementing section 353 of the PHSA are
contained in 42 CFR part 493.
Section 353(p)(2) of the PHSA provides for the exemption of
laboratories from CLIA requirements in States that enact legal
requirements that are equal to or more stringent than CLIA's statutory
and regulatory requirements. Section 353(p)(2) of the PHSA is
implemented in subpart E of our regulations at 42 CFR part 493.
Sections 493.551(a) and 493.553 provide that CMS may exempt from CLIA
requirements, for a period not to exceed 6 years, all State-licensed or
State-approved laboratories in a State if the State licensure program
meets the specified conditions. Section 493.559(a) provides that CMS
will publish a notice in the Federal Register when CMS grants an
exemption to an approved State licensure program. Section 493.559(b)
provides that the notice will include the following:
The name of the State licensure program.
A description of how the laboratory requirements of the
State are equal to or more stringent than those of part 493.
The basis for granting the exemption.
The term of approval, not to exceed 6 years.
A. State of Washington's Application for CLIA Exemption of Its
Laboratories
The State of Washington has applied for exemption of its
laboratories from CLIA program requirements. The State of Washington
submitted all the applicable information and attestations required by
Sec. Sec. 493.551(a), 493.553, and
[[Page 22407]]
493.557(b) for State licensure programs seeking exemption of their
licensed laboratories from CLIA program requirements. Examples of
documents and information submitted include: a comparison of its
laboratory licensure requirements with the comparable CLIA condition-
level requirements (that is, a crosswalk); and a description of the
following: its inspection process; its proficiency testing (PT)
monitoring process; its data management and analysis system; its
investigative and response procedures for complaints received against
laboratories; and its policy regarding announced and unannounced
inspections.
B. CMS Analysis of Washington's Application and Supporting
Documentation
To determine whether CMS should grant a CLIA exemption to
laboratories licensed by a State, CMS reviews the application and
additional documentation that the State submits to us and conducts a
detailed and in-depth comparison of the State licensure program and
CLIA's statutory and regulatory requirements to determine whether the
State licensure program meets the requirements in part 493.
In summary, the State generally must demonstrate that:
It has State laws in effect that provide for a State
licensure program that has requirements that are equal to, or more
stringent than, CLIA condition-level requirements for laboratories.
It has implemented a State licensure program with
requirements that are equal to, or more stringent than, the CLIA
condition-level requirements such that a laboratory licensed by the
State program would meet the CLIA condition-level requirements if it
were inspected against those requirements.
The requirements under that State licensure program meet
or exceed the requirements of Sec. Sec. 493.553, 493.555, and
493.557(b) and is suitable for approval by CMS under Sec.
493.553(b)(3). For example, among other things, the program would need
to:
++ Demonstrate that it has enforcement authority and administrative
structures and resources adequate to enforce its laboratory
requirements.
++ Permit CMS or CMS agents to inspect laboratories within the
State.
++ Require laboratories within the State to submit to inspections
by CMS or CMS agents as a condition of licensure.
++ Agree to pay any costs associated with our activities to
validate its State licensure program as specified in Sec.
493.557(b)(4) as well as the State's pro rata share of the general
overhead to develop and implement CLIA as specified in Sec.
493.649(a).
++ Take appropriate enforcement action against laboratories found
by CMS or CMS agents to be out of compliance with requirements
equivalent to CLIA requirements, as specified in Sec. 493.557(b).
As specified in our regulations at Sec. Sec. 493.555 and
493.557(b), our review of a State licensure program includes (but is
not necessarily limited to) an evaluation of the following:
Whether the State's requirements for laboratories are
equal to, or more stringent than, the CLIA condition-level
requirements.
The State's inspection process requirements to determine
the following:
++ The comparability of the full inspection and complaint
inspection procedures to those of CMS, including, but not limited to,
inspection frequency and the ability to investigate and respond to
complaints against its laboratories.
++ The State's enforcement procedures for laboratories found to be
out of compliance with its requirements.
The ability of the State to provide CMS with electronic
data and reports with the adverse or corrective actions resulting from
PT results that constitute unsuccessful participation in CMS-approved
PT programs and with other data CMS determines to be necessary for
validation review and assessment of the State's inspection process
requirements.
The State's agreement with CMS that requires the State to
do the following:
++ Notify CMS within 30 days of the action taken against any CLIA-
exempt laboratory that has had its licensure or approval suspended,
withdrawn, revoked, or limited; been in any way sanctioned; or had any
adverse action taken against it.
++ Notify CMS within 10 days of any deficiency identified in a
CLIA-exempt laboratory in cases when the deficiency poses an immediate
jeopardy to the laboratory's patients or a hazard to the general
public.
++ Notify each laboratory licensed by the State under its approved
State licensure program within 10 days of a withdrawal of our approval
of the State's licensure program, and the resulting loss of the
laboratory's exemption from CLIA based on its licensure under that
program.
++ Provide CMS with written notification of any changes in the
State's licensure (or approval) and inspection requirements.
++ Disclose to CMS or CMS' agent any laboratory's PT results in
accordance with the State's confidentiality requirements.
++ Take appropriate enforcement action against laboratories that
CMS or CMS agents find to be out of compliance with CLIA condition-
level requirements and report these enforcement actions to CMS.
++ Notify CMS within 30 days of all newly licensed laboratories,
including the specialty and subspecialty areas of testing, and notify
CMS of any changes in the specialties and subspecialties for which any
licensed laboratory in the State performs testing.
++ Provide CMS with inspection schedules, as requested, for
validation purposes.
In keeping with the process described above, CMS evaluated the
application and supporting materials that were submitted by Washington
State to verify that the laboratories licensed through its program will
meet or exceed the requirements of the following subparts of part 493:
Subpart H, Participation in Proficiency Testing for
Laboratories Performing Nonwaived Testing;
Subpart J, Facility Administration for Nonwaived Testing;
Subpart K, Quality Systems for Nonwaived Testing,
Subpart M, Personnel for Nonwaived Testing;
Subpart Q, Inspection; and
Subpart R, Enforcement Procedures.
CMS found that Washington State's laboratory licensure program
requirements mapped to all the CLIA condition-level requirements. The
State licensure program's inspection process and PT monitoring
processes were adequate. Other materials that were submitted
demonstrated compliance with the other above-referenced requirements of
subpart E of part 493. As a result, CMS concluded that the submitted
documents supported exempting laboratories licensed under that program
from the CLIA program requirements. Furthermore, a review of our
validation inspections conducted by the CMS office in Seattle,
Washington, supported this conclusion.
The Federal validation inspections of CLIA-exempt laboratories, as
specified in Sec. 493.563, were conducted on a representative sample
basis, as well as in response to any substantial allegations of
noncompliance (complaint inspections). The outcome of those validation
inspections has been and will continue to be our principal tool for
verifying that the laboratories located in, and licensed by, the State
are in compliance with CLIA requirements.
[[Page 22408]]
The CMS office in Seattle, Washington, has conducted validation
inspections of a representative sample of the laboratories inspected by
the Washington State Office of Laboratory Quality Assurance (LQA). The
validation inspections were primarily of the concurrent type; that is,
our surveyors accompanied Washington State's inspectors, each
inspecting against his or her agency's respective regulations. Analysis
of the validation data revealed no significant differences between the
State and Federal findings. The validation surveys verified that the
State of Washington inspection process covers all CLIA conditions
applicable to each laboratory being inspected and also verified that
the State laboratory licensure requirements meet or exceed CLIA
condition-level requirements. The validation surveys found the State
inspectors highly skilled and qualified. The LQA inspected laboratories
in a timely fashion; that is, all laboratories were inspected within
the required 24-month cycle. All parameters monitored by the CMS office
in Seattle, Washington, to date, indicate that the State of Washington
is meeting all requirements for approval of CLIA exemption. This
Federal monitoring will continue as an on-going process.
C. Conclusion
Based on review of the documents submitted by the Washington State
licensure program under the requirements of subpart E of part 493, as
well as the outcome of the validation inspections conducted by the CMS
office in Seattle, Washington, CMS finds that the State of Washington's
licensure program meets the requirements of Sec. 493.553(a), and that,
as a result, CMS may exempt all State-licensed laboratories from CLIA
program requirements.
Approval of the CLIA exemption for laboratories located within and
licensed by the State of Washington laboratory licensure program is
subject to removal if CMS determines that the outcome of a
comparability review or a validation review inspection is not
acceptable, as described under Sec. Sec. 493.573 and 493.575, or if
the State of Washington fails to pay the required fee every 2 years as
required under Sec. 493.649.
D. Laboratory Data
The approval of this exemption for laboratories located within and
licensed by the State of Washington is conditioned on the State of
Washington's continued compliance with the assertions made in its
application, including the provision of information to us in accordance
with our regulations at Sec. 493.557(b)(8) about changes to a
laboratory's specialties or subspecialties based on the State's survey,
and changes to a laboratory's certification status.
E. Required Administrative Actions
CLIA is a user-fee funded program. The registration fee paid by
laboratories is intended to cover the cost of the development and
administration of the program. However, when a State's application for
exemption is approved, CMS does not charge a fee to laboratories in the
State. The State's share of the costs associated with CLIA must be
collected from the State, as specified in Sec. 493.649.
The State of Washington must pay for the following:
Costs of Federal inspections of laboratories in the State
to verify that standards are being enforced in an appropriate manner.
Costs incurred for investigations of complaints against
State of Washington laboratories if the complaint is substantiated.
The State's pro rata share of general overhead to
administer the laboratory certification program under section 353 of
the PHS Act.
To estimate the State of Washington's proportionate share of the
general overhead costs to develop and implement CLIA, CMS determined
the ratio of laboratories in the State to the total number of
laboratories nationally. Approximately 1.9 percent of the registered
laboratories are in the State of Washington. CMS determined that a
corresponding percentage of the applicable CMS, CDC, FDA, and their
respective contractor costs should be borne by the State of Washington.
The State of Washington has agreed to pay the State's pro rata
share of the anticipated overhead costs and costs of actual validation
(including complaint investigation surveys) as specified in Sec.
493.655(b). A final reconciliation for all laboratories and all
expenses will be made. CMS will reimburse the State for any overpayment
or bill it for any balance.
II. Approval
In light of the foregoing, CMS grants approval of the State of
Washington's laboratory licensure program under subpart E. All
laboratories located in and licensed by the State of Washington under
the Medical Test Site law, chapter 70.42 of the Revised Code of
Washington, are CLIA-exempt for all specialties and subspecialties
until April 1, 2028.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Trenesha Fultz-Mimms, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-06802 Filed 3-29-24; 8:45 am]
BILLING CODE 4120-01-P